• share
• favorite_border

Wistar and Leiden University Medical Center (LUMC) formalized a memorandum of understanding between the two institutions to explore a postdoctoral training exchange program in immunology, cancer research and vaccine biology. The Wistar-Schoemaker International Postdoctoral Fellowship would bring recent Ph.D. graduates trained at LUMC to Wistar to advance their research education under the mentorship of cutting-edge biomedical research leaders.

• share
• favorite_border

Wistar scientists applied synthetic DNA-based technology to drive in vivo production of broadly neutralizing anti-HIV antibodies in small and large-animal models, providing proof of concept for a simple and effective next generation approach to HIV prevention and therapy. These results were published online in the Journal of Clinical Investigation.

• share
• favorite_border

The American Cancer Society has awarded a Research Professorship to Wistar's Dmitry l. Gabrilovich, M.D., Ph.D. This lifelong designation, accompanied by a five-year $400,000 commitment, is the most prestigious research grant made by ACS.

• share
• favorite_border

Wistar and collaborating institutions have received a major grant from the National Institutes of Health to further research on new melanoma targeted therapies integrating the role of the tumor microenvironment in influencing response to therapy and development of resistance.

• share
• favorite_border

Wistar scientists described a novel mechanism through which astrocytes, the most abundant supporting cells in the brain, also promote cancer cell growth and metastasis in the brain.

• share
• favorite_border

A novel anticancer molecule created by researchers at The Wistar Institute showed therapeutic activity in preclinical models of various cancer types.

• share
• favorite_border

The National Institutes of Health (NIH) today announced that Zachary T. Schug, Ph.D., assistant professor in the Molecular & Cellular Oncogenesis Program at Wistar, was awarded the prestigious NIH Director’s New Innovator Award in support of his research on the link between a high sugar/fat diet, alcohol use and cancer.

• share
• favorite_border

Wistar was awarded two major grants totaling more than $12 million from the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health, to fund an international multidisciplinary clinical research consortium spearheaded by Wistar’s HIV Research Program.

• share
• favorite_border

Wistar researchers have described the role of mitochondrial fission factor (MFF) in controlling survival of cancer cells, suggesting the protein could represent a promising therapeutic target.

• share
• favorite_border

Wistar has received a grant of approximately $4.6 million from the National Institutes of Health in support of innovative research to tackle antibiotic resistance.

• share
• favorite_border

Contrary to the long-held view that semen can only act as a way to transmit HIV-1 from men to women, scientists at The Wistar Institute and the University of Puerto Rico found that frequent and sustained semen exposure can change the characteristics of the circulating and vaginal tissue immune cells that are targets for infection, reducing the susceptibility to a future infection.

• share
• favorite_border

New research from The Wistar Institute sheds light on the function of the ARID1A protein, encoded by a gene that is among the most frequently mutated across human cancers.

• share
• favorite_border

Wistar and the University of South Florida researchers have advanced a novel compound that specifically targets the endoplasmic reticulum (ER) stress response that is frequently hyperactivated in cancer and promotes survival of cancer cells during stressful conditions.

• share
• favorite_border

The Wistar Institute’s Cancer Center has received an “exceptional” rating on its Cancer Center Support Grant (CCSG) application from the National Cancer Institute (NCI) for the second review cycle in a row and the grant has been recommended for renewal, providing $13.6 million to the Cancer Center scientific enterprise.

• share
• favorite_border

New approach for delivery of DNA-encoded monoclonal antibodies (DMAbs) has been reported by Wistar scientists. This new technology allows direct production of monoclonal antibody-like molecules in living animals.

• share
• favorite_border

Researchers at The Wistar Institute have created a drug candidate for cancers associated with Epstein-Barr Virus (EBV), the virus that causes infectious mononucleosis.

• share
• favorite_border

Researchers at The Wistar Institute have described a novel role of nicotinamide adenine dinucleotide (NAD+) metabolism in the ability of senescent cells to release tumor-promoting molecules.

• share
• favorite_border

Collaborative research by The Wistar Institute and Moffitt Cancer Center has demonstrated that BRAF targeted therapies render resistant melanoma more sensitive to the attack of killer T cells.

• share
• favorite_border

The Wistar Institute announces that it was awarded more than $16M in federal research funds in support of its groundbreaking research in cancer, immunology and infectious diseases.

• share
• favorite_border

A novel, synthetic DNA vaccine developed at The Wistar Institute induces protective immunity against Mayaro virus (MAYV), a mosquito-borne infection endemic to South America, that has the potential to become a global emerging viral threat.